Daria Mochly-Rosen, Professor of Chemical and Systems Biology, is the George D. Smith Professor for Translational Medicine and the co-director of SPARK at Stanford. Daria leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. The reseach in her lab led to the identification of a novel inhibitor of pathological mitochondrial fission, and its use in a variety of chronic diseases, including neurodegeneration. This technology provided the basis for Mitoconix, which she founded in FutuRx in 2016.
She was the chair of her department (2001-2004) and Senior Associate Dean for Research (2013-2016), has published over 250 papers, over 30 patents and founded two other companies: KAI Pharmaceuticals (2003-2011, the maker of Parsabiv for kidney dialysis patients; aquiered by Amgen and sold by Amgen and Ono since 2016), ALDEA/Aviv (2013; now licensed to Foresee).
Daria is also the founder, president and co-director of SPARK At Stanford (since 2006), which provides education in drug discovery and development and has helped over 100 inventors (60% of the participants) of biopharmaceuticals and diagnostics bring their invention to clinical studies and/or to licensing. She is the president founder of SPARKGlobal, which help establish SPARK programs in >50 academic institutions around the world, increasing the likelihood that new treatments will be developed from academic research efforts across the globe.
Dr. Mochly-Rosen holds a Ph.D. in Chemical Immunology from the Weizmann Institute of Science in Israel, and completed her postdoctoral training at University of California, Berkeley.